Research Type: Assessment

Atopic Dermatitis

Assessment

Atopic dermatitis is a chronic relapsing skin condition associated with dry skin and itching. It is characterized by acute flare-ups of pruritic lesions over dry skin Atopic dermatitis is a subset of the broad classification of eczema. It is the most common skin disease in children, with 50% of patients experiencing onset of disease within […]

Cardiovascular Disease: Atherosclerosis

Assessment

In June 2018, ICER announced its intention to assess the comparative clinical effectiveness and value of canakinumab (Novartis) for cardiovascular risk reduction in people with atherosclerosis. However, in October 2018, when the Food and Drug Administration declined to approve canakinumab’s expanded indication for atherosclerotic cardiovascular disease, ICER announced it would no longer proceed with its value assessment. […]

Opioid Epidemic: Abuse Deterrent Opioids

Assessment

Opioids are used to treat cases of acute and chronic pain that arise from a variety of causes, ranging from trauma to palliative care for advanced illness. Every year, 100 million people in the United States suffer from pain, 9-12 million of whom have chronic or persistent pain. Although opioid therapy is an important component […]

Ovarian Cancer

Assessment

ICER’s report reviews evidence on the comparative clinical effectiveness and value of poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of ovarian cancer. For questions or additional information, please contact info@icer.org. Interventions of Interest: Rucaparib (Rubraca®, Clovis Oncology) Niraparib (Zejula®, Tesaro, Inc.) Olaparib (Lynparza®, AstraZeneca) View the Key Stakeholders List. Final Documents Below you will find […]

Lupus Nephritis

Assessment

ICER plans to assess the comparative clinical effectiveness and value of voclosporin (Aurinia Pharmaceuticals, Inc.) and belimumab (BENLYSTA®, GlaxoSmithKline) for the treatment of lupus nephritis. Voclosporin is seeking an initial approval for the treatment of lupus nephritis, and belimumab is seeking a label expansion for the treatment of lupus nephritis; both are expecting FDA decisions […]

Community Health Workers

Assessment

Disparities across racial and socioeconomic lines in the utilization of health care services and in patient outcomes continue to plague healthcare systems in the U.S. Policies to address health care disparities have varied, including steps to increase access to health insurance coverage at both the state and federal levels, policies aimed at increasing the diversity […]

Cardiovascular Disease: Cardiac Nuclear Imaging

Assessment

ICER completed a Technology Assessment of cardiac nuclear imaging for the public meeting of the Washington State Health Technology Assessment Program’s Clinical Committee. Date of review: September 2013 Intervention of interest: Cardiac nuclear imaging Final Documents Below you will find the final documents from the assessment review process:

Chronic Pain: Lower Back

Assessment

Low back pain is an exceedingly common complaint, with a lifetime prevalence rangingfrom 11-84% (Walker, 2000). Chronic low back pain may be seen in as many as 75% ofpatients 6-12 months after an initial episode (Wahlgren, 1997). The economic impact of lowback pain is also substantial. It is the fifth most common reason for all […]

Migraine: Acute Therapies

Assessment

Migraine is a common cause of headache and is characterized by episodic, recurrent attacks that are classically pulsatile or throbbing, frequently involve one side of the head, and are associated with nausea and sensitivity to external stimuli such as light, sound, and smells. Migraine attacks vary in their frequency and intensity, but when severe can […]

Colorectal Cancer: CT Colonography

Assessment

Computed tomography colonography (CT colonography or CTC) is a minimally invasiveradiological technique used to provide images of the colon and rectum. CTC has been suggested as an alternative or as complementary to conventional colonoscopy and other population-based screening methods for colorectal cancer. Given that only 40%-60% of eligible patients undergo recommended screening for colorectal cancer, […]